Licensing & partnership
Pfizer Licenses Starna CAR-T Programs
Pfizer licensed three pre-IND in vivo CAR-T programs for autoimmune diseases from Starna Therapeutics, with exclusive rights outside Greater China. Starna will receive $330 million upfront and is eligible for up to $2.3 billion in development and commercial milestones, plus royalties. Pfizer will lead development outside Greater China, plans to manufacture initial clinical trial product in the United States, and has options to expand its territorial rights.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.